Mulina Injection 150 mg/15 ml contains Lefamulin Acetate, a novel pleuromutilin-class antibiotic developed for the treatment of serious bacterial infections. Lefamulin is specifically designed to combat a wide range of Gram-positive, Gram-negative, and atypical pathogens, including drug-resistant strains. It is primarily indicated for the management of community-acquired bacterial pneumonia (CABP) in adult patients who require parenteral therapy.

Lefamulin works by selectively inhibiting bacterial protein synthesis. It binds to the peptidyl transferase center of the 50S ribosomal subunit, a unique mechanism that differs from many other antibiotic classes. This targeted action helps reduce cross-resistance and ensures effective bacterial eradication, even against organisms resistant to macrolides, fluoroquinolones, and beta-lactam antibiotics.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Mulina Injection is indicated for the treatment of adults with community-acquired bacterial pneumonia caused by susceptible microorganisms, including:

• Streptococcus pneumoniae

• Staphylococcus aureus (including methicillin-susceptible strains)

• Haemophilus influenzae

• Mycoplasma pneumoniae

• Chlamydophila pneumoniae

• Legionella pneumophila

Dosage and Administration

Mulina Injection is intended for intravenous administration only. The recommended dosage and duration of therapy should be determined by the physician based on the severity of infection, patient condition, and clinical response. The injection should be administered as a slow intravenous infusion under medical supervision.

Key Benefits

• Broad-spectrum antibacterial coverage, including atypical pathogens

• Effective against resistant respiratory pathogens

• Unique mechanism of action with low cross-resistance potential

• Suitable for hospitalized patients requiring IV therapy

• Clinically proven efficacy in community-acquired bacterial pneumonia

Precautions and Warnings

• Use with caution in patients with known hypersensitivity to lefamulin or pleuromutilin antibiotics

• May cause QT interval prolongation; caution is advised in patients with cardiac conditions

• Not recommended during pregnancy unless clearly necessary

• Liver function should be monitored during prolonged therapy

• Drug interactions may occur with strong CYP3A4 inhibitors or inducers

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Adverse Effects

Commonly reported adverse effects may include:

• Nausea and vomiting

• Diarrhea

• Infusion site reactions

• Elevated liver enzymes

• Headache

Most side effects are mild to moderate and resolve with continued therapy or discontinuation as advised by a healthcare professional.

Storage Conditions

Store Mulina Injection below 30°C, protected from light and moisture. Keep out of reach of children. Do not use if the solution shows signs of discoloration or particulate matter.

Conclusion

Mulina Injection 150 mg/15 ml (Lefamulin Acetate) is a modern, targeted antibacterial agent offering an effective intravenous treatment option for community-acquired bacterial pneumonia. Its novel mechanism, broad coverage, and activity against resistant pathogens make it a valuable choice in hospital and clinical settings where advanced antibiotic therapy is required.